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Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of
these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize
systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies
involving cytotoxic chemotherapy and biologic agents including targeted therapies such as anti-HER-2, anti-EGFR
therapies, and therapies directed at c-kit. Although the results of most trials are modest at best, there has
been an increase in studies for salivary cancer in recent years and there are several promising treatment
approaches in evolution. Every effort should be made to treat salivary gland malignancies under a clinical
protocol and/or at a large multidisciplinary practice with clinicians experienced in treating these malignancies.
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Salivary gland malignancies are morphologically and
clinically varied neoplasms and account for approxi-
mately 5–7 % of head and neck cancers. Salivary
gland malignancies can occur throughout the upper
aerodigestive tract but the majority of tumors occur
in the parotid gland and other major salivary glands
[1]. The heterogeneity of salivary malignancies is
underscored by the World Health Organization classi-
fication, which categorizes these tumors into 24 subtypes
with varying biologic characteristics, clinical behaviors,
and survival outcomes [2].
Systemic therapy for salivary gland cancers has been
a longstanding problem for medical oncologists. Many
malignant salivary cancers are largely cured with sur-
gery alone but oncologists routinely encounter such
subtypes as adenoid cystic carcinoma (ACC), adeno-
carcinoma NOS, carcinoma ex-pleomorphic adenoma,* Correspondence: chintakuntlawar.ashish@mayo.edu
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carcinoma (SDC) in the recurrent and metastatic set-
ting. The clinical behaviors of the various types of
salivary cancers range from aggressive to indolent,
with heterogeneity even within any given subtype,
making treatment standardization a challenge. Regardless
of the type of salivary cancer, the majority of patients with
metastatic salivary gland cancer will succumb to the dis-
ease, and metastatic disease remains incurable.
Surgical resection is the cornerstone of treatment
for salivary gland malignancies. Radiotherapy is often
employed as adjuvant therapy for tumors deemed to
be at high risk of recurrence or as definitive treat-
ment when surgical resection is not feasible. The role
of chemotherapy in the definitive treatment of salivary
cancer remains to be defined. The potential benefit of
adding platinum chemotherapy to adjuvant radiother-
apy for high-risk salivary cancer is currently under in-
vestigation in RTOG 1008 (NCT01220583), and the
results of this randomized trial will hopefully inform fu-
ture management. For now, the use of chemotherapy inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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to the clinical judgment of the treating physician. The pri-
mary use of chemotherapy or systemic therapy is for pa-
tients with recurrent or metastatic disease for whom
surgery or radiotherapy is not possible. Rigorous testing
or standardization of systemic therapies in metastatic or
recurrent salivary gland carcinomas is extremely difficult
due to the rarity and heterogeneity of these tumors. In this
review we discuss the current knowledge about thera-
peutic options for recurrent and metastatic salivary gland
malignancies with a focus on cytotoxic chemotherapy and
biologic agents tested in the last 15 years and a look to-
wards future therapeutics.
Literature search
PubMed, Medline, and Ovid databases were searched for
studies related to systemic therapy for salivary gland car-
cinomas; lymphomas were excluded. English language
publications including reviews and abstracts from Janu-
ary 2001 to December 2015 were considered. The time
frame was restricted as there is a comprehensive review
of cytotoxic chemotherapy already published in 2006 [3].
References of the studies obtained were cross-referenced
for additional studies. Only phase 2–3 studies were con-
sidered. Select prospective studies were included if pa-
tients were chosen based on specified inclusion criteria
and if all patients were treated with a specific regimen in
a standard fashion. Select case reports/series were in-
cluded only for SDC as they are particularly clinically
relevant. Retrospective studies and duplicate studies
published as abstracts previously were excluded.
The following sections summarize key findings of re-
cent clinical trials for cytotoxic chemotherapy, targetedTable 1 Studies with cytotoxic chemotherapy alone or in combinat
Author (year) Regimen No of
patients
Histology
Airoldi et al. [6] Vino vs Cis + Vino 20 vs 16 Ad (9), ACC (22),
others (4)
Gedlicka et al. [7] Mitoxantrone + Cis 14 NR
Gilbert et al. [11] Paclitaxel 45 Ad (17), ACC (14)
van Herpen et al.[12] Gemcitabine 21 ACC (21)
Ross et al. [10] Epirubicin + Plat + 5FU 8 ACC (8)
Laurie et al. [8] Plat + Gemcitabine 33 Ad (8), ACC (10),
others (11)
Ghosal et al. [47] Cis + Imatinib 28 ACC (28)
Argiris et al. [50] Bor→ Bor + Dox 24 ACC (24)
Hitre et al. [49] Cetuximab + Cis + 5FU 12 ACC (12)
Airoldi et al. [9] Cis + Vino 60 Ad (15), ACC (34)
5FU 5-florouracil, ACC adenoid cystic carcinoma; Ad adenocarcinoma, Bor bortezomib,
Vino vinorelbine, NR not reported
anot required for adenoid cystic carcinoma
bresponse rates for Bor and Bor + Dox combination respectively
cmedian survival for first-line patients onlyand biologic agents, and combination therapies, with a
brief discussion of hormone therapy for SDC.
Cytotoxic chemotherapy
Combination therapy with platinum
The prior review of chemotherapy for advanced salivary
malignancies by Laurie et al. in 2006 reported variable
modest response rates to cytotoxic chemotherapy and
concluded that there is no standard of care cytotoxic
chemotherapy. The most studied chemotherapeutic regi-
men was the historic salivary cancer regimen cyclophos-
phamide, doxorubicin, and cisplatin [3]. The authors
concluded that there was no clear benefit for the use of
triplet therapy over single agent regimens [4, 5]. We
reviewed prospective studies from 2001 to 2015 investi-
gating cytotoxic chemotherapy for all salivary gland tu-
mors including ACC, adenocarcinoma NOS, and MEC,
with the majority of trials using chemotherapeutic com-
binations with either cisplatin or carboplatin (Table 1).
Almost half of the studies were restricted to ACC, but
the other half included other histologic subtypes albeit
in smaller numbers. Four studies in particular appear to
show support for the use of platinum doublet therapy;
all four studies included a mixed population of patients
with salivary cancer, although ACC and adenocarcinoma
predominated. One study by Airoldi et al. showed im-
proved overall response with the combination of cis-
platin and vinorelbine over vinorelbine alone (44 versus
20 %, respectively), and notably is one of the only studies
with randomized data [6]. In addition, the objective re-
sponse rate (ORR) as well as overall survival (OS)
showed a trend towards statistical significance in favor
of the combination arm. Another study investigating theion with biologic agents
Progression
required
ORR CBR Median OS
(months)
MEC (1), Yes 20 % vs 44 % 65 % vs 81 % 8.5 vs 10
No 14 % 79 % 27
, MEC (14) No 18 % 51 % 12.5
No 0 % 52 % NR
No 12 % 75 % 27
MEC (4), Yesa 24 % 82 % 13.8
No 11 % 79 % 35
Yes 0 % and 8 %b 63 % and 58%b 21
No 42 % 92 % 24
Yes 23 % 57 % 10c
Cis cisplatin, Dox Doxorubicin, MEC mucoepidermoid carcinoma, Plat platinum,
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ORR of 14 % and a median OS of 27 months [7]. A third
study by the National Cancer Institute of Canada Clin-
ical Trials Group studied platinum and gemcitabine in
patients with advanced salivary cancer with disease pro-
gression (not required for ACC patients) and reported
that the ORR was 24 % and the clinical benefit rate
(CBR) was 82 %. Four patients out of eight with adeno-
carcinoma (3 per RECIST) had a partial response and
one had a complete response [8]. Recently, a large co-
hort of 60 patients treated with cisplatin and vinorelbine
showed an ORR of 23 % with better responses seen in
the first-line setting (31 % first line versus 5 % second
line) [9]. Triplet therapy with platinum was reported in a
small study by Ross et al. investigating the combination
of cisplatin/carboplatin, epirubicin, and 5-flurouracil
(5-FU) in eight patients with ACC, seven as first-line
therapy [10]. Despite the addition of a third cytotoxic
agent, the ORR was only 12 %, further supporting the no-
tion that triplet cytotoxic regimens have no clinical benefit
for metastatic salivary cancers. Even though the ORR was
modest, the median OS was still 27 months underscoring
the often indolent clinical behavior of metastatic ACC and
the dual challenges of studying systemic therapy and hav-
ing transient disease response translate into a meaningful
survival advantage.Single agent cytotoxic chemotherapy
With the advent of interest in biologic and targeted ther-
apies, single agent chemotherapy trials have become
rare. In 2006, an Eastern Cooperative Oncology Group
study of single agent paclitaxel showed some activity
(18 %) in salivary gland carcinomas but all objective re-
sponses were seen in patients with adenocarcinoma or
MEC (29 % adenocarcinoma and 21 % MEC); no object-
ive responses were seen in patients with ACC. Despite
this differential response, the OS was comparable for all
subtypes, again highlighting the fact that systemic ther-
apy has no known survival benefit for metastatic salivary
cancer [11]. A second trial of single agent gemcitabine
exclusively in patients with ACC was completely nega-
tive with no objective responses seen [12].Biologic agents
The limited utility and efficacy of cytotoxic chemotherapy
have compelled the need for systematic study of alterna-
tive therapies for advanced salivary gland carcinomas.
With the knowledge that salivary gland carcinomas ex-
press various potential targets such as the epidermal
growth factor receptor (EGFR) [13, 14], c-kit [15], and
human epidermal growth factor receptor-2 (HER-2)
[16], numerous trials of biologic agents have been con-
ducted since 2003 (Table 2).HER-2 directed therapy
Results of HER-2 directed therapy for patients with re-
current or metastatic salivary gland cancer have been
disappointing to date, with the notable exception being
in patients with HER-2-positive SDC [17]. One the first
studies that attempted to explore the activity of trastuzu-
mab in an unselected population of advanced salivary
gland cancers was stopped early when it was found that
HER-2 positive salivary gland carcinomas are actually
very rare. Fourteen patients were ultimately enrolled
(7 ACC) with a single response seen in a patient with
MEC [18]. Lapatinib was also studied in salivary
gland carcinomas with no objective responses seen.
Of note, stable disease was reported in 78 % of pa-
tients and progressive disease was required prior to
trial enrollment [19].
EGFR-directed therapy
EGFR overexpression is seen in salivary gland carcin-
omas [13, 14] and hence single agent cetuximab and ge-
fitinib were studied in two negative phase 2 trials. Locati
et al. enrolled 30 patients (23 ACC) with no objective re-
sponses noted with single agent cetuximab [20]. Similarly,
a study by Jakob et al. in an unselected population of pa-
tients with advanced salivary malignancies reported no
objective responses to gefitinib [21]. Given the complete
lack of response to these agents, further investigation of
single agent EGFR-targeted therapy is not warranted.
Targeted therapy for c-kit
Overexpression of c-kit was demonstrated in salivary
gland carcinomas [15, 22] prompting enthusiasm for the
investigation of the c-kit-directed agents imatinib and
dasatinib. Three separate studies to date have investi-
gated the use of single agent imatinib and one study has
investigated single agent dasatinib. All of the imatinib
studies included only patients with c-kit-positive ACC
and in total included 43 patients [23–25]. One study by
Guigay et al. demonstrated a 13 % ORR to imatinib [25]
but the other two trials did not show any objective re-
sponses [23, 24]. Similarly, in a large phase 2 study, a
second generation c-kit inhibitor, dasatinib, demon-
strated no objective responses [26].
Multi-targeted tyrosine kinase inhibitors
Several multi-targeted tyrosine kinase inhibitors (TKI)
have been investigated in advanced salivary malignan-
cies, with the vast majority of the studies being con-
ducted in patients with ACC. The anti-angiogenic TKIs
sunitinib and sorafenib have shown overall disappointing
results in patients with recurrent or metastatic salivary
cancers with sorafenib having the most promise with re-
sponse rates ranging from (11–22 %). No objective re-
sponses were seen with sunitinib in patients with ACC,
Table 2 Studies with biologic agents




ORR CBR Median OS (months)
Haddad et al. [18] Trastuzumab 14 Ad (7), ACC (2), MEC (3),
others (2)
No 8 % 8 % NR
Hotte et al. [23] Imatinib 16 ACC (16) No 0 % 56 % 7
Pfeffer et al. [24] Imatinib 10 ACC (10) No 0 % 20 % NR
Guigay et al. [25] Imatinib 17 ACC (17) Yes 13 % 47 % NR
Agulnik et al. [19] Lapatinib 39 Ad (7), ACC (20), MEC (2),
others (11)
Yes 0 % 78 % NR (ACC), 13.8 (non-ACC)
Locati et al. [20] Cetuximab 30 ACC (23), MEC (2), others (5) No 0 % 80 % NR
Chau et al. [27] Sunitinib 14 ACC (14) Yes 0 % 85 % 18.7
Jaspers et al. [44] Bicalutamide 10 SDC (10) No 20 % 50 % 12
Locati et al. [29] Sorafenib 37 ACC (19), others (18) No 16 % 73 % NR
Thomson et al. [28] Sorafenib 23 ACC (23) No 11 % 79 % 19.6
Kim et al. [34] Everolimus 34 ACC (34) Yes 0 % 79 % 23.7
Goncalves et al. [37] Vorinostat 30 ACC (30) No 3 % 87 % NR
Hoover et al. [36] Nelfinavir 15 ACC (15) Yes 0 % 47 % NR
Ho A. et al. [30] Axitinib 33 ACC (33) Yes 9 % 85 % NR
Locati et al. [43] Bicalutamide + Triptorelin 17 SDC (17) No 65 % 88 % 44
Wong et al. [26] Dasatinib 54 ACC (40), others (14) Yes 2 % 50 % 14.5 (ACC), NR (non-ACC)
Jakob et al. [21] Gefitinib 36 Ad (9), ACC (18), MEC (2),
others (6)
No 0 % 59 % 25.9 (ACC); 16 (non-ACC)
Dillon et al. [32] Dovitinib 35 ACC (35) Yes 6 % 71 % 22.1
Ho A. et al. [35] MK-2206 16 ACC (16) Yes 0 % 93 % NR
Keam et al. [31] Dovitinib 32 ACC (32) Yes 3 % 94 % NR
Ad adenocarcinoma, ACC adenoid cystic carcinoma, MEC mucoepidermoid carcinoma, NR not reported
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ease and the median OS was 18.7 months; progression
within 6 months prior to study therapy was required
[27]. Sorafenib has been studied in two trials – one re-
stricted to patients with ACC and one in a mixed popu-
lation, with non-ACC patients potentially deriving more
benefit. Thomson et al. reported an 11 % ORR and a
19.6 month median OS in patients with ACC [28]. Simi-
larly, Locati et al. reported an overall response rate of
16 % with differential response seen in ACC versus non-
ACC patients (11 vs 22 %) [29].
Several TKIs have been studied exclusively in patients
with ACC; unfortunately, ACC remains an exceptionally
treatment-resistant disease. Axitinib - a small molecule
inhibitor of vascular endothelial growth factor (VEGF),
c-kit, and platelet derived growth factor receptor
(PDGFR) - produced three partial responses (9 % ORR)
in a single center trial for ACC [30]. Dovitinib -an oral
tyrosine-kinase inhibitor that inhibits VEGF and fibro-
blast growth factor receptors (FGFR) - showed minimal
activity in two trials (ORR 3 % and 6 %) and poor toler-
ability with grade 3/4 asthenia reported in >50 % of pa-
tients [31, 32]. Genetic analysis of tumors of patients
with ACC showed that a significant number of tumorshad mutations involving the FGF-PI3K-AKT pathway
[33], however the AKT-inhibitor MK-2206 and the
mTOR inhibitor everolimus showed no responses in
ACC patients [34, 35]. Similarly, nelfinavir, a proteosome
inhibitor, shown to be efficacious in AKT-inhibition, also
demonstrated no objective responses in patients with
ACC [36]. Even though ACC might have epigenetic dys-
regulation as a pathogenic mechanism [33], vorinostat -a
histone deacetylase inhibitor - failed in an early trial with
a reported response rate of 3 % [37].
Although the search for effective targeted therapies for
patients with advanced salivary cancer has been elusive,
the number of agents being tested continues to increase
and recent reports of prolonged disease control in well-
designed clinical trials offers some hope for optimism re-
garding future therapies. At the annual meeting of the
American Society of Clinical Oncology (ASCO) in 2016,
an unprecedented number of therapeutic trials for recur-
rent/metastatic salivary gland malignancies were pre-
sented. In a phase II study that required documented
disease progression prior to enrollment, pazopanib – a
multi-kinase inhibitor of VEGFR, PDGFR, and KIT – re-
sulted in prolonged stable disease in both ACC adenoid
cystic and non-ACC patients. Although the response
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ACC), the trial met its primary endpoint of 6-month
PFS greater than 40 % [38]. Similarly a trial of ninteda-
nib targeting VEGFR1-3, PDGFRα/β, and FGFR1-2 had
a disease control rate of 75 % and a 6-month PFS >60 %,
although it was not clear if disease progression was re-
quired prior to enrollment [39]. Regorafenib, a multi-
kinase inhibitor of VEGFR, FGFR, and PDGFR, resulted
in prolonged stable disease (>6 months) in ACC patients
who had documented progression prior to initiation of
therapy [40]. Notably, the microtubular inhibitor eribulin
showed a 10 % objective partial response rate in a mixed
population of salivary patients, but a striking 69 % of pa-
tients had some tumor shrinkage on first tumor assess-
ment and the disease control rate was reported at 90 %
[41]. Further exploration of the use of eribulin for saliv-
ary cancers appears warranted, and the verdict is still
out on the role of multi-kinase inhibitors which perhaps
may play a role in select clinical situations or in combin-
ation with immunotherapy. Fusion transcripts, such as
ETV6-NTRK3 [42], characterize a portion of the salivary
gland malignancies and are potential targets for therapy
with specific inhibitors (NCT02576431).
Hormonal therapy
Although no prospective studies have been conducted,
it is worthwhile mentioning the data for androgen
deprivation in SDC as several reports have emerged
in recent years and results have been promising.
Retrospective data from a single institution where pa-
tients were treated uniformly with bicalutamide and
triptorelin showed an impressive ORR of 65 % [43].
In contrast another retrospective study showed an
ORR of 20 %. However, the latter study did not treat
patients uniformly and most were not treated with a
gonadotropin releasing hormone receptor agonist [44].
Recently, case reports have also demonstrated the effect-
iveness of second-line hormone therapy with abiraterone,
a CYP17 inhibitor, after failure of first-line androgen
deprivation [45, 46]. Currently, a randomized trial is un-
derway in Europe to study the efficacy of androgen
deprivation therapy in androgen receptor-positive salivary
cancers (NCT01969578).
Combination therapy with cytotoxic chemotherapy and
biologics
After initial enthusiasm about the possible responses in
c-kit overexpressing ACC [15, 22], cisplatin was studied
in combination with imatinib. Imatinib was given as an
induction regimen at 800 mg daily for 8 weeks followed
by the combination of imatinib 400 mg daily with cis-
platin 80 mg/m2 intravenously every 4 weeks. If patients
had stable or responding disease, then imatinib was con-
tinued as maintenance therapy. There were only threeresponses but the median OS was 35 months [47]. As
previously mentioned, ACC frequently overexpress
EGFR [13, 14]. Hitre et al. studied a regimen similar to
the EXTREME regimen [48] in patients with ACC and
reported a response rate of 42 % in a cohort of 12 meta-
static patients [49]. Finally, a study of the combination of
bortezomib, a proteasome inhibitor, and doxorubicin
showed minimal response in patients with ACC although
the clinical benefit rate for the combination was reported
at 58 % [50]. To date, there are no biologic therapies or
combinations with chemotherapy that have a clear benefit
for patients with advanced salivary cancer.
Immunotherapy
With the current landscape of cancer therapeutics shift-
ing towards immunotherapy, the obvious question is
whether patients with salivary cancer will benefit from
these agents. At the present time there is very limited
preclinical data for the role of immune checkpoint in-
hibitors in salivary gland malignancies. A recent study
showed that Programmed death Ligand-1 is differentially
expressed in various histologies and is a poor prognostic
marker for disease-free survival and possibly for overall
survival [51]. Despite the lack of robust preclinical data,
clinical trials of immune checkpoint inhibitors in salivary
cancer are underway. At the 2016 ASCO meeting, pre-
liminary results of the salivary arm of the phase 1b
KEYNOTE-028 trial were presented. In the study, pa-
tients with advanced salivary cancer (73 % previously
treated) received single agent pembrolizumab 10 mg/kg
intravenously every 2 weeks for up to 24 months. A total
of 26 patients were enrolled with mixed salivary histolo-
gies. Three PRs were seen (11.5 %), all in non-ACC pa-
tients (two adenocarcinoma, one high-grade serous
carcinoma). Twelve patients (46 %) had stable disease
and the 6-month PFS was 20.7 % [52]. The role of pem-
brolizumab monotherapy in salivary cancers continues
to be investigated in the phase 2 KEYNOTE-158 basket
trial (NCT02628067). Combination immunotherapy or
immunotherapy in combination with other agents for
salivary cancer is also being investigated in ongoing
trials including ipilimumab combined with nivolumab
(NCT02834013), oncolytic adenovirus in combination
with pembrolizumab (NCT02576431), and histone deace-
tylase (HDAC) inhibitors in combination with pembroli-
zumab (NCT02538510). The early signal of efficacy in the
KEYNOTE-028 trial opens the door for cautious opti-
mism for immunotherapy in salivary cancers, particular
non-ACC histologies.
Discussion
Salivary gland carcinomas, especially ACC, are notori-
ously resistant to therapy and no standard of care exists.
Platinum-based chemotherapy, if chemotherapy is given,
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cious enough to be considered standard of care. Rarity
of these tumors, heterogeneity in behavior, and compos-
ition of subjects in each trial make it extremely difficult
to systematically study potential new therapies and to
compare results across trials and over time. Although in
recent years there has been greater success at conduct-
ing subtype-specific trials, at least for ACC. Of note, the
number of trials published for salivary cancer has stead-
ily climbed from 0 to 1 per year in the time period
2008–2010 to 4–6 per year in the period from 2014 to
2015, a remarkable feat given the rarity of salivary can-
cer, and a critical step in finding novel therapeutic ap-
proaches for this disease.
As with many solid tumors, there is often a discrepancy
between preclinical data, possible therapeutic mecha-
nisms, and the results of clinical trials. We have yet to find
effective targeted therapy that is widely applicable to saliv-
ary gland carcinomas. Multiple reports had demonstrated
the expression of several potential targets in salivary can-
cers including c-kit, EGFR, and HER-2, thus prompting a
new generation of trials [14–16, 22] Despite strong
scientific rationale, imatinib and dasatinib failed to
demonstrate clinical benefit. One confounding factor
was the heterogenous criteria for c-kit staining, and
the lack of ability to correlate the degree of positive
of c-kit staining with response [53]. Similarly, there is
no data to determine whether the response rates are
correlated to any c-kit mutations. However, c-kit mu-
tations are not very common in salivary gland carcin-
oma [15]. Despite the fact that the genomic landscape
of ACC is known [33], there is not a clear direction
forward for salivary cancers as a whole. Individualized
medicine may offer the most benefit for patients with
the ability to test for driver mutations in individual
patients and to tailor therapy to the patient’s tumor,
from both a clinical and molecular standpoint.
Despite the overall modest results of new trials of
chemotherapeutic and biologic agents, there are some
notable glimmers of hope on the horizon for the treat-
ment of advanced salivary cancers. Adenocarcinoma of
the salivary gland appears to be more treatment respon-
sive with a higher likelihood of benefit from cytotoxic
chemotherapy and a preliminary signal of responsiveness
to immune checkpoint inhibitors [8, 9, 11, 49]. The micro-
tubular inhibitor eribulin deserves further evaluation given
the promising disease control rate and initial tumor
shrinkage that was reported in a mixed population of sal-
ivary patients; further defining which subtypes benefit the
most from this agent would be helpful. The use of hor-
mone therapy and anti-HER2 therapy for salivary duct
carcinoma or AR+/HER2+ adenocarcinoma is a treatment
approach that should continue to be refined and investi-
gated. The head and neck medical oncology communitywill be eagerly awaiting the results of future trials of
immunotherapy-based treatments that hopefully will
move the practice forward and break through the thera-
peutic plateau that has likely been reached for cytotoxic
agents; further refinement of our use of targeted agents
should continue. Given the clinical rarity and nuances of
each salivary cancer subtype and the changing academic
landscape with a steadily increasing number of therapeutic
options and clinical trials, management by an experienced
head and neck medical oncologist at a tertiary referral
center or academic institution is preferred if possible. Pa-
tients with advanced salivary cancers should have the op-
portunity to participate in salivary cancer-specific trials
and/or to have access to genomic testing to open the door
for appropriate phase 1 clinical trials or individualized tar-
geted treatment with the off-label use of available agents.
An experienced oncologist who sees a significant number
of patients with advanced salivary cancer will be able to
appreciate the clinical and biologic variability even within
a certain subtype of salivary cancer, and to avoid a “once
size fits all” approach which has not worked for this pa-
tient population.
From a practical standpoint, how do we typically ap-
proach our patients with advanced salivary malignan-
cies? With the lack of high quality evidence to guide
treatment and the heterogeneity of the tumors, a stand-
ard of care treatment approach to patients with recur-
rent or metastatic salivary is difficult to devise but with
the available data we generally follow the approach out-
lined in Fig. 1. If the patient has a low disease burden
with isolated or oligometastatic disease that is amenable
to local therapies, then we typically recommend local
therapy with stereotactic body radiation therapy or
cryoablation. If a patient does not have an adequate per-
formance status, then best supportive care is appropri-
ate. In a fit patient the need to treat is balanced with the
risks of systemic therapy. In a patient with slow growing,
indolent disease such as classic ACC, we prefer observa-
tion. If therapy is required due to disease burden, symp-
toms, or an aggressive clinical course, or if the patient
desires treatment (after discussion of risks and benefits),
we consider systemic treatment with either standard
chemotherapy, targeted therapy, or a clinical trial (pre-
ferred). In patients for whom chemotherapy is indicated
we most commonly would use a platinum doublet. We
routinely perform genomic testing for all patients with
recurrent or metastatic salivary cancer to see if targeted
therapy can be used either off-label or through a phase 1
clinical trial. For patients with adenocarcinoma and SDC
we routinely perform androgen receptor staining and
HER-2 testing. If they are strongly positive for androgen
receptor then we prefer treating them with combined
androgen–deprivation therapy with bicalutamide and
leuprolide, or leuprolide alone, or with anti-HER-2
Fig. 1 Our approach to treatment of patients with recurrent or metastatic salivary gland malignancies
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staining). Those patients with an initial response to an-
drogen deprivation therapy who subsequently progress
will often be treated with second-line hormone therapy
with abiraterone.
Conclusion
It has been challenging to find effective therapies for sal-
ivary cancers but it is imperative that we continue to
pursue research studies. Laurie and colleagues have put
forth some recommendations for testing therapies in
rare tumors such as salivary gland malignancies to in-
crease coordination, avoid duplication, and increase ac-
crual to clinical trials [54]. The studies reviewed here
provide no standard of care for the treatment of salivary
gland malignancies, but suggest a future landscape of
heterogenous and individualized treatment for patients
with salivary cancer. The advent of immunotherapy and
the increase in clinical trials in recent years for salivary
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